Ligand-Binding Mass Spectrometry to Study Biotransformation of Fusion Protein Drugs and Guide Immunoassay Development: Strategic Approach and Application to Peptibodies Targeting the Thrombopoietin Receptor
- 13 July 2010
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 12 (4) , 576-585
- https://doi.org/10.1208/s12248-010-9218-9
Abstract
The knowledge of in vivobiotransformation (e.g., proteolysis) of protein therapeutic candidates reveals structural liabilities that impact stability. This information aids the development and...Keywords
This publication has 15 references indexed in Scilit:
- Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedsideBritish Journal of Haematology, 2010
- Monoclonal antibodies for targeted therapy in colorectal cancer.Cancer Biology & Therapy, 2010
- Comparison of protein enrichment strategies for proteome analysis of plasmaProteomics, 2010
- Prolonged activity of factor IX as a monomeric Fc fusion proteinBlood, 2010
- Development of Different Analysis Platforms with LC−MS for Pharmacokinetic Studies of Protein DrugsAnalytical Chemistry, 2009
- Romiplostim in chronic immune thrombocytopenic purpuraClinical Therapeutics, 2009
- Evaluation of Three Principally Different Intact Protein Prefractionation Methods for Plasma Biomarker DiscoveryJournal of Proteome Research, 2008
- Mass spectrometry-based immunoassays for the next phase of clinical applicationsExpert Review of Proteomics, 2006
- Intact‐protein based sample preparation strategies for proteome analysis in combination with mass spectrometryMass Spectrometry Reviews, 2004
- Functional analysis of chemically synthesized derivatives of the human CC chemokine CCL15/HCC‐2, a high affinity CCR1 ligandChemical Biology & Drug Design, 2004